Skip to main content
logo
Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price on May 15, 2026

Soleno Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
285.01190.41----
Cost of Revenue
3.92.7----
Gross Profit
281.11187.71----
Selling, General & Admin
153.24132.13105.8613.489.8410.81
Research & Development
38.3840.6378.5725.1915.2721.45
Other Operating Expenses
3.055.543.242.71-0.71-0.73
Total Operating Expenses
194.68178.29187.6741.3824.431.53
Operating Income
86.449.41-187.67-41.38-24.4-31.53
Interest Income
18.5516.9512.052.580.30.11
Interest Expense
-5.41-5.48-0.23---
Other Non-Operating Income (Expense)
----0.180.030.51
Total Non-Operating Income (Expense)
13.1411.4811.822.40.330.62
Pretax Income
99.5820.89-175.85-38.99-24.07-30.91
Provision for Income Taxes
3.54-----
Net Income
96.0420.48-175.85-38.99-24.07-30.91
Net Income Attributable to Preferred Dividends
00.42----
Net Income to Common
96.0420.48-175.85-38.99-24.07-30.91
Shares Outstanding (Basic)
5251401685
Shares Outstanding (Diluted)
5352401685
Shares Change (YoY)
24.73%30.39%143.61%96.40%57.90%27.39%
EPS (Basic)
1.820.40-4.38-2.36-2.87-5.81
EPS (Diluted)
1.770.39-4.38-2.36-2.87-5.81
Shares Outstanding
51.7252.2945.731.688.165.32
Free Cash Flow
105.4246.73-69.31-24.94-20.79-27.79
Free Cash Flow Growth
125.62%-----
Free Cash Flow Per Share
1.980.89-1.73-1.51-2.48-5.23
Gross Margin
98.63%98.58%----
Operating Margin
30.33%4.94%----
Profit Margin
33.70%10.97%----
FCF Margin
36.99%24.54%----
EBITDA
88.4611.43-185.68-39.43-22.43-29.57
EBITDA Margin
31.04%6.00%----
EBIT
86.449.41-187.67-41.38-24.4-31.53
EBIT Margin
30.33%4.94%----
Effective Tax Rate
3.55%0.00%0.00%0.00%0.00%0.00%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q